Kobo Biotech

How has been the historical performance of the Kobo Biotech?

Kobo Biotech experienced significant financial decline from March 2013 to March 2014, with net sales dropping from Rs 403.66 crore to Rs 103.19 crore, resulting in a loss of Rs 34.82 crore after tax and a negative earnings per share of Rs -15.47. Overall, the year was marked by decreasing revenues and increasing losses.

Answer:<BR>The historical performance of Kobo Biotech shows significant fluctuations in key financial metrics over the years.<BR><BR>Breakdown:<BR>Kobo Biotech's net sales have seen a decline from Rs 403.66 crore in March 2013 to Rs 103.19 crore in March 2014. This drop is mirrored in total operating income, which also fell from Rs 403.66 crore to Rs 103.19 crore in the same period. The company's total expenditure, excluding depreciation, decreased from Rs 360.78 crore in March 2013 to Rs 108.80 crore in March 2014, leading to an operating profit (PBDIT) that shifted from a profit of Rs 43.24 crore to a loss of Rs 0.68 crore. Consequently, the profit before tax turned negative, dropping from Rs 14.87 crore in March 2013 to Rs -34.27 crore in March 2014, resulting in a profit after tax of Rs -34.82 crore. The earnings per share (EPS) reflected this downturn, falling from Rs 6.07 to Rs -15.47. On the balance sheet, total liabilities remained stable at Rs 411.68 crore, while total assets also held steady at Rs 411.68 crore. Cash flow from operating activities decreased significantly, from Rs 36.72 crore in March 2013 to Rs 6.72 crore in March 2014, contributing to a net cash outflow of Rs -10.84 crore. Overall, Kobo Biotech's financial performance in March 2014 indicates a challenging year marked by declining revenues and increasing losses.

how big is Kobo Biotech?

As of Jun 06, Kobo Biotech Ltd has a market capitalization of 6.41 Cr, classifying it as a Micro Cap company, with recent net sales of 0.00 Cr and a net profit of -5.04 Cr. Shareholder's funds are valued at 87.89 Cr, and total assets amount to 411.68 Cr.

Market Cap: As of Jun 06, Kobo Biotech Ltd has a market capitalization of 6.41 Cr, which classifies it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Kobo Biotech reported net sales of 0.00 Cr and a net profit of -5.04 Cr. This data is based on Standalone financials.<BR><BR>Balance Sheet Snapshot: The balance sheet data is Consolidated and pertains to the reporting period of Mar'14. Shareholder's funds are valued at 87.89 Cr, while total assets amount to 411.68 Cr.

Who are the top shareholders of the Kobo Biotech?

The top shareholders of Kobo Biotech are Arch Pharmalabs Ltd with 44.95%, and individual investors who own 48.27%. The largest public shareholder is Mehul Pravin Chandra Shah at 1.1%, with no mutual funds or foreign institutional investors involved.

The top shareholders of Kobo Biotech include Arch Pharmalabs Ltd, which holds the largest share at 44.95%. Additionally, individual investors collectively own 48.27% of the company. The highest public shareholder is Mehul Pravin Chandra Shah, who holds 1.1%. There are no mutual funds or foreign institutional investors currently holding shares in the company.

What does Kobo Biotech do?

Kobo Biotech Ltd is a micro-cap manufacturer of active pharmaceutical ingredients, established in 1992 and formerly known as Avon Lifesciences. As of June 2024, it reported a net profit of -1 Cr and has a market cap of Rs 6 Cr.

Overview: <BR>Kobo Biotech Ltd is a customer-centric manufacturer of active pharmaceutical ingredients (API) operating in the Commodity Chemicals industry within the micro-cap market.<BR><BR>History: <BR>Kobo Biotech Ltd was established as a Public Limited Company on August 3, 1992, and changed its name from Avon Lifesciences Ltd to Kobo Biotech Limited on October 19, 2020. The most recent quarterly results reported are for June 2024.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: -1 Cr (Quarterly Results - Jun 2024) <BR>Market-cap value: Rs 6 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 47 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -1.05 <BR>Return on Equity: 3.71% <BR>Price-to-Book: -0.05<BR><BR>Contact Details: <BR>Address: Ground Flr D No 8-2-684/J/8/A, Bhavani Nagar Banjara Hills Hyderabad Telangana : 500034 <BR>Email: info@avonlifesciences.com <BR>Phone: N/A <BR>Website: N/A

When is the next results date for Kobo Biotech?

No Upcoming Board Meetings

Has Kobo Biotech declared dividend?

Kobo Biotech Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 21, 2012. However, the company has shown significant fluctuations in total returns, with negative returns in shorter periods and a positive return only over the 5-year period.

Kobo Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: Sep-21-2012<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was -17.16%, the dividend return was 0%, resulting in a total return of -17.16%.<BR><BR>In the 1-year period, the price return was -42.43%, the dividend return was 0%, resulting in a total return of -42.43%.<BR><BR>In the 2-year period, the price return was 3.72%, the dividend return was 0%, resulting in a total return of 3.72%.<BR><BR>In the 3-year period, the price return was -52.64%, the dividend return was 0%, resulting in a total return of -52.64%.<BR><BR>In the 4-year period, the price return was -58.1%, the dividend return was 0%, resulting in a total return of -58.1%.<BR><BR>In the 5-year period, the price return was 28.72%, the dividend return was 0%, resulting in a total return of 28.72%.<BR><BR>Overall, Kobo Biotech has declared a dividend, but the total returns over various periods show significant fluctuations, with negative returns dominating in the shorter time frames and a positive return only in the 5-year period. The lack of a current dividend yield indicates that recent performance may not be favorable for investors seeking income from dividends.

Who are the peers of the Kobo Biotech?

Kobo Biotech's peers include Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Gujarat Alkalies, Grauer & Weil, and Padmanabh Inds. In terms of performance, India Glycols leads with a 1-year return of 150.39%, while Kobo Biotech has the lowest at -39.28%.

Peers: The peers of Kobo Biotech are Tata Chemicals, Chemplast Sanmar, GHCL, India Glycols, Fischer Medical, Gujarat Alkalies, Grauer & Weil, and Padmanabh Inds.<BR><BR>Quality Snapshot: Excellent management risk is observed at GHCL, while Good management risk is found at Chemplast Sanmar. Average management risk is present at Tata Chemicals, India Glycols, and Grauer & Weil, while Below Average management risk is seen at Fischer Medical and Gujarat Alkalies. The remaining peers, Kobo Biotech and Padmanabh Inds., do not qualify for management risk assessment. In terms of growth, all peers except for Fischer Medical and GHCL show Below Average growth, while Fischer Medical has Average growth and GHCL does not qualify. Capital Structure ratings reveal Excellent ratings for GHCL and Gujarat Alkalies, Average for Tata Chemicals and Grauer & Weil, and Below Average for Chemplast Sanmar and India Glycols, with Kobo Biotech and Padmanabh Inds. not qualifying.<BR><BR>Return Snapshot: India Glycols has the highest 1-year return at 150.39%, while Kobo Biotech has the lowest at -39.28%. Kobo Biotech's 1-year return is significantly lower than all peers. Additionally, Gujarat Alkalies, Grauer & Weil, and Tata Chemicals have negative six-month returns.

Are Kobo Biotech latest results good or bad?

Kobo Biotech's latest results for Q1 2024 are disappointing, showing a decline in financial health with an operating profit of Rs -0.34 crore and a profit before tax of Rs -1.35 crore, leading to a 'Sell' recommendation from MarketsMOJO. Investors should be cautious due to these negative trends.

Kobo Biotech's latest financial results for the quarter ending March 2024 indicate a challenging period for the company. The performance has been flat, with a score of -3, reflecting a decline in financial health compared to the previous quarter. <BR><BR>The operating profit (PBDIT) was recorded at Rs -0.34 crore, marking the lowest point in the last five quarters, which suggests a negative trend in operational performance. Similarly, the profit before tax (PBT) also hit its lowest at Rs -1.35 crore, indicating ongoing struggles with profitability.<BR><BR>Earnings per share (EPS) fell to Rs -0.56, again the lowest in recent quarters, which is not favorable for shareholders. Overall, the results have fallen below expectations, and the 'Sell' call from MarketsMOJO further emphasizes the negative outlook for the company. Investors should be cautious and consider these trends before making any investment decisions.

Is Kobo Biotech overvalued or undervalued?

As of April 25, 2023, Kobo Biotech is considered overvalued and risky due to its negative financial metrics, including a PE ratio of -1.30 and a one-year stock return of -43.42%, significantly underperforming compared to healthier peers like Godrej Industries.

As of 25 April 2023, Kobo Biotech's valuation grade has moved from does not qualify to risky, indicating a significant deterioration in its financial standing. The company is currently assessed as overvalued, primarily due to its negative PE ratio of -1.30, an EV to EBITDA ratio of -145.92, and a ROCE of -74.85%. These ratios highlight severe profitability issues and suggest that the company is struggling to generate positive returns.<BR><BR>In comparison to its peers, Kobo Biotech's financial metrics starkly contrast with those of Godrej Industries, which has a PE ratio of 46.63 and an EV to EBITDA of 34.36, indicating a much healthier valuation. Other peers like Solar Industries are considered very expensive with a PE ratio of 123.77. Additionally, Kobo Biotech's recent stock performance has been poor, with a one-year return of -43.42%, significantly underperforming the Sensex's 7.61% return over the same period. This further reinforces the notion that the company is overvalued in its current state.

What is the technical trend for Kobo Biotech?

As of May 26, 2025, Kobo Biotech's technical trend has shifted to bearish, supported by negative MACD, Bollinger Bands, and moving averages across multiple time frames, along with poor performance against the Sensex.

As of 26 May 2025, the technical trend for Kobo Biotech has changed from mildly bearish to bearish. The current stance is bearish with strong indicators supporting this view. The MACD is bearish on both the weekly and monthly time frames, and Bollinger Bands also reflect a bearish trend in both time frames. Daily moving averages confirm the bearish sentiment. The KST is bearish on both weekly and monthly charts, while the Dow Theory indicates a mildly bearish stance on the weekly and monthly levels. Overall, the strength of the bearish trend is reinforced by the negative performance against the Sensex, particularly over the past year and three years.

Who are in the management team of Kobo Biotech?

As of March 2022, the management team of Kobo Biotech includes Ajit Kamath (Chairman), Rajendra Kaimal, Jignesh Patel (Company Secretary), Sunil Pitroda, Abhishek Buddhadev, and Urja Shah, with a mix of executive and non-executive roles focused on governance and compliance.

As of March 2022, the management team of Kobo Biotech includes the following individuals:<BR><BR>1. Ajit Kamath - Chairman (Non-Executive)<BR>2. Rajendra Kaimal - Non-Executive & Non-Independent Director<BR>3. Jignesh Patel - Company Secretary & Compliance Officer<BR>4. Sunil Pitroda - Non-Executive & Independent Director<BR>5. Abhishek Buddhadev - Non-Executive & Independent Director<BR>6. Urja Shah - Non-Executive & Independent Director<BR><BR>This team comprises a mix of executive and non-executive roles, with a focus on governance and compliance.

Should I buy, sell or hold Kobo Biotech Ltd?

Why is Kobo Biotech Ltd falling/rising?

As of 05-May, Kobo Biotech Ltd's stock price is stable at 2.71, with a mixed performance: a 4.91% decline in the past week, a 12.45% rise over the last month, and a 13.39% increase year-to-date. Despite recent gains, it has underperformed its sector today by 5.61, though increased investor participation suggests potential for future price changes.

As of 05-May, Kobo Biotech Ltd's stock price is currently stable at 2.71, with no change noted (0.00%). However, the stock has shown a mixed performance over different periods. In the past week, it has fallen by 4.91%, while over the last month, it has risen by 12.45%. Year-to-date, the stock has increased by 13.39%, contrasting with a decline of 3.21% over the past year.<BR><BR>Despite the recent gains over the month and year-to-date, the stock has underperformed its sector today by 5.61%. Additionally, the trading activity has been erratic, with the stock not trading on 4 out of the last 20 days, indicating potential volatility or lack of consistent investor interest. <BR><BR>On a positive note, there has been a significant increase in investor participation, as evidenced by a delivery volume of 35.46k on April 21, which rose by 327.2% compared to the 5-day average. This suggests that while the stock is currently stable, there is a growing interest among investors, which could influence future price movements positively.<BR><BR>Overall, the stock's current stability at 2.71 reflects a combination of recent gains, erratic trading patterns, and increasing investor participation, which may contribute to its potential for future price changes.

Which are the latest news on Kobo Biotech?